EMA Priority Medicines (PRIME)
For medicine developers, the European Medicines Agency priority medicines route is a key early access tool. The priority medicines scheme, better known as PRIME, is designed for new medicines that target an unmet medical need and may deliver a major therapeutic advantage over existing treatments.
PRIME is not approval. It is a voluntary scheme that gives early and proactive support so medicine developers can build robust data, show the medicine’s benefits, and enable accelerated assessment later.
What are priority medicines at EMA?
The European Medicines Agency launched the PRIME scheme in 2016 to target medicines under development that are not yet authorised in the EU and are intended for an initial centralised marketing authorisation application. EMA’s priority medicines scheme focuses on medicines of major public health interest, where existing treatments are inadequate.
The priority medicines scheme targets therapeutic areas with high unmet medical need, including oncology, neurology, vaccines, and advanced therapies. As of recommendations adopted by March 2026, 26% of PRIME requests had been granted, and 67% had been denied, showing how selective PRIME eligibility remains.
Why the scheme matters
The benefit of the PRIME scheme is timing. The European Medicines Agency engages in earlier stages of development, when the development plan and robust data package can still change.
EMA’s PRIME scheme is built to strengthen support around evidence generation. In the first five years, EMA found that PRIME support helped shorten clock stops and improve patient access for approved medicines.
PRIME eligibility criteria
The eligibility criteria for the PRIME scheme are closely linked to those used for accelerated assessment, but they are applied earlier and with greater uncertainty. PRIME eligibility depends on whether the available data suggest the medicine can address unmet medical need to a significant extent.
The European Medicines Agency says the medicine should be of major public health interest. For most applicants, that means preliminary clinical evidence in patients, not just a promising hypothesis.
Unmet medical need
An unmet medical need exists when no satisfactory method of diagnosis, prevention, or treatment is available, or when candidate medicines could meaningfully outperform existing ones. Applicants need to show more than a hard disease area. They need a clear explanation of why current care is still inadequate for patients.
That is why the priority medicines scheme asks sponsors to connect the target population, the disease burden, and the medicine’s benefits. To address unmet medical need convincingly, the case has to be clinically grounded.
Major therapeutic advantage
A major therapeutic advantage can include better morbidity, mortality, prevention, onset, or duration of disease. The European Medicines Agency guidance also points to outcomes and meaningful improvement over existing treatments.
This is one reason many PRIME application files are unsuccessful. The available data may look encouraging, but not yet robust enough to show a major therapeutic advantage or a significant improvement in clinical outcomes for patients.
When should applicants apply?
For most applicants, the right timing is during exploratory clinical development, when early patient data can show proof of concept. The PRIME scheme is less suitable when a medicine is already in late development and there is little room left for enhanced support to shape decisions.
The European Medicines Agency also says PRIME is not the right route for sponsors already in the pre submission phase of a marketing authorisation application. In those cases, other tools such as scientific advice or a separate accelerated assessment request may be more appropriate.
Early Entry PRIME status
The PRIME scheme also includes an option for earlier support. Early Entry PRIME status is available for the academic sector and micro, small, and medium sized enterprises when compelling non clinical data in a relevant model show proof of principle and first in human studies show adequate exposure and tolerability.
If that earlier route is granted, sponsors receive enhanced support before full PRIME is confirmed. That can include an introductory meeting, fee advantages for scientific advice, and a clearer path for applicants.
What support do developers get?
Once granted, medicine developers receive help. PRIME products can benefit from:
- early rapporteur appointment
- a kick off meeting
- an EMA Scientific Coordinator
- iterative scientific advice
- confirmation of the potential to enable accelerated assessment at filing.
The European Medicines Agency offers pre submission support to any sponsor planning a PRIME application. Through IRIS, applicants can request a virtual discussion on unmet medical need, PRIME eligibility, and the submitted robust data before submitting the full dossier.
Scientific advice and proactive support
Scientific advice is central to EMA’s PRIME. The PRIME scheme is designed to strengthen support through repeated interaction, so medicine developers can identify gaps early, refine their regulatory strategy, and generate more robust data for a marketing authorisation application.
That proactive support can also involve patients, HTA bodies, and FDA observers in some cases. For complex drugs, that wider dialogue helps address unmet medical need with better evidence planning.
Submission readiness meeting
The submission readiness meeting is now one of the most useful parts of the priority medicines scheme. The submission readiness meeting takes place about one year before filing and reviews dossier maturity, evidence needs, possible regulatory risks, and later evaluation.
This matters because accelerated assessment is never automatic. Under the European Medicines Agency procedure, CHMP review can be reduced from up to 210 days to 150 days, excluding clock stops, if the justification is strong enough and the request is granted.
New features in 2026
In March 2026, the European Medicines Agency made 3 pilot tools permanent in EMA’s PRIME scheme: a regulatory roadmap and product development tracker, expedited scientific advice, and the submission readiness meeting. EMA said these new features were designed to give developers faster answers and better MAA preparation.
The pilot report also said the expedited scientific advice route reduced average procedure time versus standard scientific advice. That is a practical benefit when one focused question could otherwise delay development.
PRIME and FDA pathways
Global teams often compare the priority medicines scheme with FDA programmes. The European Medicines Agency and FDA do not run mirror image systems.
PRIME is a European development support scheme linked to possible accelerated assessment. FDA breakthrough therapy designation, by contrast, is an expedited pathway for drugs where preliminary clinical evidence suggests substantial improvement over available therapy on a clinically significant endpoint.
Breakthrough therapy designation and FDA review timelines
Breakthrough therapy designation brings intensive FDA guidance and the features of Fast Track. FDA says priority review gives a six month review goal rather than ten months for applications that could represent a significant improvement.
For multinational applicants, breakthrough therapy designation does not guarantee PRIME, and PRIME does not guarantee an equivalent outcome. Still, both systems target serious conditions, unmet medical need, robust data, and clear clinical benefit over existing treatments.
When PRIME may not be the right tool
Not every promising medicine belongs in the priority medicines scheme. The European Medicines Agency says PRIME is not intended for:
- medicines already too far advanced
- or for marketing authorisation holders seeking support mainly for new indications on already authorised medicines.
The scheme was built for new medicines where earlier regulatory engagement can still change development. That matters when sponsors compare new indications with existing ones.
PRIME application checklist
A strong PRIME application should explain the unmet medical need, the weakness of existing treatments, and the expected medicine’s benefits. It should also show how the available data support a likely major therapeutic advantage and why enhanced support would still add benefit.
Applicants should think about CMC, safety, manufacturing readiness, and timing. They should target a defined population and target clear endpoints. The European Medicines Agency and FDA have joint guidance on quality and GMP issues for PRIME and breakthrough therapy designation programmes, covering control strategy, process validation, stability, and shelf life.
Operationally, applicants should use IRIS correctly and align their submission with the 2026 timetable. That helps PRIME eligibility discussions stay grounded, especially for medium sized enterprises. It can also enable accelerated assessment for eligible medicines and support smarter drug approval planning.
How Azurbio helps
Azurbio supports medicine developers that want a PRIME case. We help clients:
- define the unmet medical need argument
- test PRIME eligibility
- map the development plan,
- prepare for scientific advice, submission readiness, and accelerated assessment strategy.
We also help teams align EU and FDA planning, whether the goal is PRIME, breakthrough therapy designation, or FDA approval readiness. That is useful for innovative medicines facing regulatory challenges, complex quality questions, or pressure to bring benefit to patients faster.
FAQ
PRIME is not an approval route. It is a European Medicines Agency support scheme intended to strengthen support during development and improve the quality and benefit of a marketing authorisation application for patients.
Yes, non SMEs can apply. But only the academic sector and smaller companies can use Early Entry PRIME, which is why that route is especially valuable in earlier stages.
Yes, a medicine can still request accelerated assessment without being in PRIME. EMA states that medicines outside the scheme may still be eligible if they meet the criteria at filing.